INI-4001
INI-4001 is a TLR7/8 agonist and vaccine adjuvant. INI-4001 regulates innate and adaptive immune responses by activating murine TLR7 and human TLR7/TLR8. INI-4001 enhances IgG and neutralizing antibody responses against Powassan virus (POWV), reduces viral loads in the brain, liver and spleen, provides complete protection against lethal POWV challenge, and skews immune responses toward a Th1 phenotype. When INI-4001 is used in combination with Al (OH)3 and SARS-CoV-2 RBD antigen, it efficiently adsorbs to Al (OH)3, promotes Th1 immunity and enhances SARS-CoV-2 neutralizing antibody responses. INI-4001 is applicable to research related to Powassan virus infection and COVID-19.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2549050-07-7
- 分子式: C59H109N6O13P
- 分子量:1141.50
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
TLR7 |
TLR8 |
INI-4001 (200 μg/mL; 1 h) adsorbs efficiently to mixed formulations of aluminum oxyhydroxide (AH) and aluminum phosphate (AP) in 2% glycerin, with no desorption observed in the presence of INI-2002 or SARS-CoV-2 RBD[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
INI-4001 (10 μg per mouse; i.m.; day 0, day 14, day 42) co-delivered with SARS-CoV-2 RBD and aluminum salt (Alhydrogel or Adju-phos) significantly enhances RBD-specific IgG and Th1-skewed IgG2c antibody titers, induces robust antigen-specific Th1 (IFNγ-producing) T cell responses, and improves surrogate viral neutralization activity in C57BL/6 mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 7 weeks old at vaccination)[1]
-
Dosage:10 nmol (prime-boost vaccination); 10 nmol (single vaccination)
-
Administration:s.c.; prime-boost 2-4 weeks apart; single administration
-
Result:Induced a mean log10 IgG endpoint titer of 4.9, with 11/18 mice having measurable FRNT50 neutralizing antibody titers.
Conferred 100% survival against lethal POWV-I challenge, compared to 50% survival with alum.
Reduced POWV-I viral RNA loads in the brain, liver, and spleen compared to mock-vaccinated mice post-challenge.
Enabled passive transfer of sera to protect 4/5 naïve mice from lethal POWV-I challenge.
Maintained 100% survival against lethal POWV-I challenge even after CD4+ or CD8+ T cell depletion.
Induced cross-reactive IgG antibodies to POWV-II and Langat virus, and conferred 100% survival against lethal POWV-II challenge, compared to 40% survival with alum; vaccinated mice had minimal weight loss (max ~3% initial weight) compared to alum-vaccinated survivors (10% weight loss).
Maintained significantly higher IgG and neutralizing antibody titers than alum-vaccinated mice for 36 weeks post-boost; enabled 80% survival against lethal POWV-I challenge 36 weeks post-boost.
Conferred 100% survival against lethal POWV-I challenge with single vaccination.
化学情報
-
CAS 番号 2549050-07-7
-
分子量 1141.50
-
分子式 C59H109N6O13P
-
SMILES
OC1=NC2=C(N)N=C(O[C@@H](C)CCC)N=C2N1CC3CCN(CCOP(OCCOCCOCCOC[C@H](OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O)(O)=O)CC3
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (270 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
INI-4001 関連分類
HY-164485 関連分類
Powered by Bioz